1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
April 4, 2001
---------------------------------
(Date of earliest event reported)
ATRIX LABORATORIES, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
DELAWARE 0-18231 84-1043826
---------------------------- --------------------- ---------------------------------
(State or Other Jurisdiction (Commission File No.) (IRS Employer Identification No.)
of Incorporation)
2579 MIDPOINT DRIVE, FORT COLLINS, COLORADO 80525
(Address of principal executive offices, including zip code)
(970) 482-5868
----------------------------------------------------
(Registrant's telephone number, including area code)
2
Item 5. Other Events.
On April 4, 2001, Atrix Laboratories, Inc. (the "Company") entered into
definitive agreements with MediGene Aktiengesellschaft ("MediGene") granting
MediGene the exclusive right to market in Europe the Company's Leuprogel(TM) 1-,
3-, 4- and 6- month products--a leuprolide acetate product for subcutaneous
depot injection for the treatment of advanced prostate cancer. In connection
with the transaction, the Company and MediGene entered into a Stock Purchase
Agreement and a Collaboration, License and Supply Agreement (the "Collaboration
Agreement").
The Collaboration Agreement is attached hereto as Exhibit 99.1 and the
Stock Purchase Agreement is attached hereto as Exhibit 99.2.
Item 7. Exhibits.
99.1** Collaboration, License and Supply Agreement, dated as of April
4, 2001, by and between the Company and MediGene.
99.2** Stock Purchase Agreement, dated as of April 4, 2001, by and
between the Company and MediGene.
--------
** Confidential treatment requested.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ATRIX LABORATORIES, INC.
By: /s/ Brian G. Richmond
-------------------------------------
Brian G. Richmond
Chief Financial Officer
Date: June 14, 2001
4
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------- -----------
99.1** Collaboration, License and Supply Agreement, dated as of April
4, 2001, by and between the Company and MediGene.
99.2** Stock Purchase Agreement, dated as of April 4, 2001, by and
between the Company and MediGene.
THE SYMBOL "[**]" IS USED TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
--------
** Confidential treatment requested.